Payment overview · 2025
General Payments
$441.64
19 reported records · 9 companies
Healthcare provider profile · identity verified
Peter Xuepeng Tan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ARCADIA, CA · NPI 1144228909
Verified facts
What the public records show
CMS Open Payments records show Peter Xuepeng Tan, M.D. received $441.64 in general payments during 2025 across 19 reported records.
PFIZER INC. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Paxlovid, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.27 | 21.8% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.73 | 15.8% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.40 | 14.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.06 | 11.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.18 | 10.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.53 | 9.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $27.36 | 6.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $27.27 | 6.2% | 1 | 2025 |
| VIVUS LLC | Unresolved — no canonical attribution shown | $19.84 | 4.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $441.64 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $81.17 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.73 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $57.29 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $57.29 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $57.29 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $49.06 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.18 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $38.98 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $27.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| PANCREAZE Normalized: pancreaze |
Drug | VIVUS LLC | $19.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 116 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 33 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
107 | 22 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 25 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 598 | 175 |
| Amlodipine Besylate | Amlodipine Besylate | 466 | 129 |
| Losartan Potassium | Losartan Potassium | 370 | 116 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 295 | 98 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 289 | 105 |
| Metformin Hcl | Metformin Hcl | 283 | 86 |
| Zolpidem Tartrate | Zolpidem Tartrate | 168 | 49 |
| Trazodone Hcl | Trazodone Hcl | 167 | 45 |
| Meloxicam | Meloxicam | 165 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 150 | 36 |
| Omeprazole | Omeprazole | 143 | 45 |
| Famotidine | Famotidine | 138 | 55 |
| Montelukast Sodium | Montelukast Sodium | 130 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 121 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 33 |
| Azithromycin | Azithromycin | 117 | 101 |
| Jardiance | Empagliflozin | 116 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 108 | 72 |
| Farxiga | Dapagliflozin Propanediol | 107 | 22 |
| Amoxicillin | Amoxicillin | 102 | 71 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 99 | 37 |
| Alendronate Sodium | Alendronate Sodium | 92 | 28 |
| Vascepa | Icosapent Ethyl | 89 | 12 |
| Januvia | Sitagliptin Phosphate | 84 | 13 |
| Lorazepam | Lorazepam | 82 | 20 |
| Gabapentin | Gabapentin | 80 | 32 |
| Glimepiride | Glimepiride | 80 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 74 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 35 |
| Carvedilol | Carvedilol | 68 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | 17 |
| Celecoxib | Celecoxib | 66 | 24 |
| Allopurinol | Allopurinol | 61 | 15 |
| Metformin Hcl Er | Metformin Hcl | 61 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 13 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 54 | 14 |
| Baclofen | Baclofen | 53 | 25 |
| Simvastatin | Simvastatin | 50 | 19 |
| Eliquis | Apixaban | 49 | 11 |
| Glipizide | Glipizide | 49 | 12 |
| Prednisone | Prednisone | 48 | 28 |
| Valsartan | Valsartan | 44 | 15 |
| Cephalexin | Cephalexin | 43 | 40 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 43 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 43 | 11 |
| Atenolol | Atenolol | 42 | 15 |
| Donepezil Hcl | Donepezil Hcl | 42 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 33 |
| Lisinopril | Lisinopril | 39 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Dutasteride | Dutasteride | 37 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 36 | 12 |
| Meclizine Hcl | Meclizine Hcl | 36 | 29 |
| Mupirocin | Mupirocin | 36 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Furosemide | Furosemide | 32 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 16 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Linzess | Linaclotide | 29 | 13 |
| Irbesartan | Irbesartan | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Finasteride | Finasteride | 27 | 12 |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Ciclopirox | Ciclopirox | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 22 |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 24 | 12 |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 12 |
| Temazepam | Temazepam | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Kerendia | Finerenone | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 19 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Acarbose | Acarbose | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | suppressed |
| Rhopressa | Netarsudil Mesylate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $441.64 · 19 records | PFIZER INC. | ABRYSVO, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, EVENITY, GARDASIL 9, JARDIANCE, Kerendia, MOUNJARO, PANCREAZE, PAXLOVID, PREVNAR 20, SHINGRIX, TRELEGY ELLIPTA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error